Slide 1: Investor Presentation Q1 and Q2 2011 FY 12
For personal use only INVESTOR PRESENTATION Q1 AND Q2 2011 FY 12 This presentation contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are not guarantees of SomnoMed's future performance and involve a number of risks and uncertainties that may c
Slide 2: Topics
Topics For personal use only FINANCIAL HIGHLIGHTS 1st Half FY 2012 vs. FY 2011 OVERVIEW by Region OUTLOOK Q3 & Q4 2 © SomnoMed 2012
Slide 3: Key points 1st Half FY 11/12
Key points 1st Half FY 11/12 For personal use only • Estimated sleep apnea therapy global market growth ~ 12-15% p.a. unchanged • SomnoMed performance trending in line with guidance FY 11/12 • U.S.Medicare reimbursement for the entire product platform SomnoDent • Opening of new SomnoMed subsidiaries
Slide 4: Financial Highlights
Financial Highlights 1st Half FY 2012 vs 1st Half FY 2011 For personal use only Group operating EBITDA profit before posted $246k Corporate/ Group Gross R&D was Margin SomnoDent improved to improved to Apnea unit A$1.5 m 66% compared sales to 64% in 2010 SALES REVENUE + 26% to 14,443 devices + 14% t
Slide 5: SomnoDent unit sales
SomnoDent unit sales For personal use only CAGR UNITS 62% TO DECEMBER 2011 UNIT CONTRIBUTION PER REGION TO DECEMBER 2011 9000 Units sold per quarter 8000 Total 7000 6000 5000 4000 3000 2000 1000 0 5 © SomnoMed 2012
Slide 6: SomnoMed Progress
SomnoMed Progress Half Year to December For personal use only 6 © SomnoMed 2012
Slide 7: Financial Performance
Financial Performance For personal use only 11/12 10/11 09/10 08/09 07/08 06/07 FINANCIAL SUMMARY ( $000'S ) 1st H 1st H 1st H 1st H 1st H 1st H Units 14,443 11,450 9,140 5,475 2,916 1,870 Revenue 6,846 5,975 4,989 3,180 1,497 1,104 Gross Margin 4,515 3,825 2,847 1,655 728 486 Gross Margin% 66.0% 64
Slide 8: Investment in Growth, Innovation & Operational Excellence
Investment in Growth, Innovation & Operational Excellence For personal use only • Growth ~ $750k: U.S. Sales and Marketing Acquisition and opening new subsidiaries in EU Global MATRx Marketing pre-FDA clearance • Innovation & Operational G2 design and FDA registration Excellence ~ $400k: ISO 13485 c
Slide 9: Highlights by Region
Highlights by Region For personal use only Japan Continued growth with increasing number of SomnoMed Dental Network partners. Australia/ New Zealand/ Asia SomnoMed attended the World Sleep Market leadership with SomnoDent conference in Kyoto, More than 40% volume growth with SomnoBrux Oct 11. Expand
Slide 10: Highlights by Region
Highlights by Region For personal use only Europe Significant volume growth of more than 50% Nordic and Central European region are key drivers Record sales in December and Qtr2 First OAT insurance contract signed in Germany Acquisition of Dutch distributor 10 © SomnoMed 2012
Slide 11: Highlights by Region
Highlights by Region For personal use only North America Investments in Sales & Marketing to support future growth SomnoMed Dental Network has grown to over 1,800 members Expanding SomnoMed Medical Network Record unit sales in December 2011 and for Qtr2 11 © SomnoMed 2012
Slide 12: Outlook 2nd Half FY 11/12
Outlook 2nd Half FY 11/12 For personal use only BUSINESS PERFORMANCE ON TRACK WITH GUIDANCE FY 11/12 • Expected market launch in Q4* of SomnoDent G2 the next generation of the world’s # 1 oral sleep apnea appliance. The SomnoDent G2 will again raise the standard in comfort, compliance and treatment
Slide 13: Thank you
For personal use only Thank you ... for sharing our vision and passion to grow SomnoMed into a strong global company with a bright future... 13 © SomnoMed 2012
Slide 14: Contacts
Contacts For personal use only Chairman Dr Peter Neustadt Chief Executive Officer Mr Ralf Barschow Address Level 3, 20 Clarke Street Crows Nest NSW 2065 Australia Telephone +61 (0)2 9467 0400 Website www.somnomed.com.au